Bacteraemia – European Clinical Trials Information Network

Comparing piperacillin-tazobactam and meropenem for treating bloodstream infections caused by cephalosporin-resistant bacteria in adult patients

Wed, 29 Apr 2026 15:06:35 +0000

This study focuses on treating bloodstream infections (bacteremia) caused by specific bacteria that are resistant to certain antibiotics. The research compares two different antibiotic treatments: piperacillin-tazobactam and meropenem. The bacteria being studied include several types that commonly cause infections in the blood, such as Escherichia coli, Klebsiella species, and other related bacteria that have developed resistance to commonly used antibiotics.

The purpose of this research is to determine if piperacillin-tazobactam works as effectively as meropenem in treating these resistant blood infections. Both medications are given through an intravenous infusion, which means they are administered directly into the bloodstream. Piperacillin-tazobactam can be given up to 18 grams per day, while meropenem can be given up to 3 grams per day.

During the study, patients will receive one of these two antibiotic treatments. The doctors will monitor how well the infection responds to treatment, checking for signs of improvement or failure over several months. They will also watch for any side effects and track whether the infection returns. The study will look at various outcomes, including how long patients need to stay in the hospital and whether they develop any new infections during the treatment period.

Study Comparing Oral Fluoroquinolones or Trimethoprim-Sulfamethoxazole to IV Therapy in Stable Patients with Gram-Negative Blood Infections

Wed, 29 Apr 2026 15:04:43 +0000

This clinical trial is focused on patients with Gram-negative bacteremia, a type of blood infection caused by certain bacteria. The study is comparing two treatment approaches for these infections. One group of patients will continue receiving antibiotics through an intravenous (IV) line, which is a method of delivering medication directly into the bloodstream. The other group will switch to taking antibiotics orally, which means by mouth, once they are stable. The antibiotics being studied include fluoroquinolones and a combination of trimethoprim-sulfamethoxazole. These medications are commonly used to treat bacterial infections.

The purpose of the study is to determine if switching to oral antibiotics is as effective as continuing with IV antibiotics in terms of patient survival within 30 days. Participants in the study will be randomly assigned to one of the two treatment groups. The study will monitor patients for 90 days to observe their recovery, any side effects, and the overall effectiveness of the treatment. The study aims to provide insights into whether an early switch to oral antibiotics can be a safe and effective option for treating Gram-negative bacteremia.

Throughout the study, researchers will collect data on various outcomes, such as the number of days patients spend in the hospital, any complications related to the treatment, and the overall cost of care. This information will help determine the best approach for managing these infections and could potentially lead to changes in how they are treated in the future. The study is expected to conclude by March 2026.

Study on Shortened Antibiotic Treatment for Gram-negative Bacteremia in Hospitalized Adults Using Pivmecillinam Hydrochloride and Drug Combination

Wed, 29 Apr 2026 15:01:27 +0000

This clinical trial is focused on studying the treatment of Gram-negative bacteremia, a type of blood infection caused by certain bacteria. The study aims to evaluate the effectiveness and safety of a shorter course of antibiotic treatment, specifically 5 days, compared to the traditional 7 days or more. The antibiotics being studied include Selexid (containing pivmecillinam hydrochloride), Ciprofloxacin, Bioclavid (containing amoxicillin and clavulanic acid), Trimopan (containing trimethoprim), Nitrofurantoin, Nebcina (containing tobramycin), Piperacillin/Tazobactam, Sulfametoxazol med trimetoprim, Sulfametizol, Meropenem, Hexamycin (containing gentamicin), Ciprofloxacin Fresenius Kabi, Ampicillin, Ertapenem, and Ceftazidim. Some of these medications are administered as tablets, while others are given as injections or infusions.

The purpose of the study is to determine if a shorter duration of antibiotic treatment is just as effective and safe for treating Gram-negative bacteremia that originates from a urinary tract infection in adults who are otherwise healthy. Participants in the study will receive either a 5-day or a longer course of antibiotics, and their health will be monitored to assess the outcomes. The study will track various health indicators, including survival rates and any potential side effects of the antibiotics, over a period of up to 90 days.

Participants will be randomly assigned to one of the treatment groups, and the study will not be blinded, meaning both the participants and the researchers will know which treatment is being administered. The study is designed to ensure that all participants receive appropriate care and that their health is closely monitored throughout the trial period. The ultimate goal is to find a treatment approach that is both effective and minimizes the duration of antibiotic use, which can help reduce the risk of antibiotic resistance and other complications.